Investigating Sotagliflozin with Insulin Therapy in Type 1 Diabetes

Overview of the Trial

A clinical trial explored the effects of sotagliflozin in combination with insulin therapy on blood glucose control in individuals with type 1 diabetes mellitus (T1DM). This research signals a potential new era of enhanced blood glucose management for T1DM patients. While insulin therapy is vital for maintaining glucose levels within a target range, challenges remain in preventing and managing hypoglycemia, or low blood sugar.

Introduction to Sotagliflozin

Sotagliflozin represents a promising new treatment option that inhibits two proteins involved in glucose regulation. By blocking these proteins, the drug improves glycemic control post-meals and reduces glucose excretion in urine. As the first dual-inhibitor studied in humans, sotagliflozin may also decrease the risk of hypoglycemia.

Details of the inTandem3 Clinical Trial

The phase III inTandem3 clinical trial took place at 134 sites worldwide, involving 1,400 adults with type 1 diabetes who were utilizing either insulin pumps or multiple-injection therapy. The multiple-injection approach includes one or two long-acting insulin injections alongside rapid or short-acting insulin before meals. The study aimed to compare the safety and efficacy of two dosages of sotagliflozin (200 mg and 400 mg) combined with insulin therapy against insulin therapy alone.

Positive Outcomes of the Trial

After 52 weeks, researchers assessed the various treatment effects. They focused on the safety of sotagliflozin as well as its impact on blood glucose levels and body weight. Participants receiving either sotagliflozin dosage alongside insulin therapy exhibited improved blood glucose control and a reduction in body weight. Additionally, those on sotagliflozin required a lower total daily insulin dose compared to the insulin-only group. The reported adverse events were 3.2% less frequent in the sotagliflozin group compared to those not taking the medication.

Concerns Identified in the Study

While the benefits are notable, researchers found that inhibiting one of the proteins involved in blood sugar management raised the risk of diabetic ketoacidosis (DKA), a serious diabetes complication characterized by high levels of blood acids. Patients taking sotagliflozin experienced a higher incidence of DKA. However, the research team emphasized that this risk could be effectively managed through increased monitoring and patient education.

Implications of the Findings

The inTandem3 trial results indicate that patients using sotagliflozin alongside insulin therapy may achieve improved blood glucose management. Given that millions of individuals worldwide live with type 1 diabetes, these findings hold significant promise for enhancing health outcomes and quality of life.

References

1. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. NEJM. https://www.nejm.org/doi/full/10.1056/nejmoa1708337. Published December 14, 2017. Accessed July 4, 2018.
2. Diabetes. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/diabetes. Published September 16, 2022. Accessed December 13, 2022.